# Randomized, double-blind, placebo-controlled trial of monthly injectable buprenorphine for methamphetamine use disorder (MURB) (CTN-0110)

> **NIH NIH N01** · THE EMMES COMPANY, LLC · 2021 · $1,406,983

## Abstract

Randomized, double-blind, placebo-controlled trial of monthly injectable buprenorphine for methamphetamine use disorder (MURB) (CTN-0110)

## Key facts

- **NIH application ID:** 10505738
- **Project number:** 75N95019D00013-0-759502100004-1
- **Recipient organization:** THE EMMES COMPANY, LLC
- **Principal Investigator:** Paul VanVeldhuisen
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,406,983
- **Award type:** —
- **Project period:** 2021-07-01 → 2024-06-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10505738

## Citation

> US National Institutes of Health, RePORTER application 10505738, Randomized, double-blind, placebo-controlled trial of monthly injectable buprenorphine for methamphetamine use disorder (MURB) (CTN-0110) (75N95019D00013-0-759502100004-1). Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/grant/nih/10505738. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*